Gerhard Gmaschitz

Synthesis of MDM2-p53 Inhibitor BI-0282 via a Dipolar Cycloaddition and Late-Stage Davis–Beirut Reaction

Harald Weinstabl, A. Gollner, Jale Karolyi-Oezguer, 2022, Organic process research & development.

Fragment Optimization of Reversible Binding to the Switch II Pocket on KRAS Leads to a Potent, In Vivo Active KRASG12C Inhibitor

A. Waterson, D. Rudolph, M. Gmachl, 2022, Journal of medicinal chemistry.

A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivo

Julian E. Fuchs, M. Koegl, Barbara Mair, 2022, Nature Communications.

Targeted Synthesis of Complex Spiro[3H‐indole‐3,2′‐pyrrolidin]‐2(1H)‐ones by Intramolecular Cyclization of Azomethine Ylides: Highly Potent MDM2–p53 Inhibitors

Julian E. Fuchs, Joachim Broeker, D. Rudolph, 2018, ChemMedChem.